NEW YORK, Feb 15 (Reuters) - Invitae Corp (NVTAQ.PK), opens new tab received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a ...

Invitae, a biotech company focusing on genetic testing, laid off 15% of its staff as the company initiated a cost-cutting plan. At the end of 2022, the company had around 1,700 employees. Beyond the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company has been on a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. In a release it put out late Tuesday ...

BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae, a leading medical genetics company ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Labcorp has been selected as the winning bidder in a process to acquire genetic specialist Invitae’s assets. The Burlington, NC-based company said it is acquiring the assets for $239 million in cash ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...